HIVManagement.org

 
Quick Menu / Table of Contents
Introduction Principles Management NRTI Info NNRTI Info
PI Info Fusion Inhibitors Coreceptor Inhibitors Integrase Inhibitors Drug Summary
Coformulation Antiretroviral Therapy
Investigational Adherence Lab Evaluation Resistance Tests PEP
Antiretroviral Tables OI Prevention Vaccinations TB Therapy Hepatitis Therapy
OI Diagnosis OI Therapy Bibliography Links Palliative Therapy

 

dolutegravir

Detailed Prescribing Information

 

Dolutegravir = Tivicay
Dosing Forms 50 mg tablets
Dosing 50 mg once a day for persons who harbor HIV WITHOUT integrase strand transfer inhibitor (INSTI) mutations; 50 mg twice a day for person WITH integrase strand transfer inhibitor (INSTI) mutations
Hepatic insufficiency: No adjustment is necessary for mild to moderate hepatic impairment.  There is no information regarding severe hepatic insufficiency.
Renal insufficiency: No adjustment needed
Food dependence May be taken with or without food
Adverse Effects Side effects appear to be very similar to placebo
Interactions Rifampin: adjust dose of dolutegravir to 50 mg twice a day

Efavirenz: adjust dose of dolutegravir to 50 mg twice a day

Ritonavir-boosted fosamprenavir: adjust dose of dolutegravir to 50 mg twice a day

Ritonavir-boosted tipranavir: adjust dose of dolutegravir to 50 mg twice a day

Substitutes for the drugs listed above should be used if possible.

Contraindications None
Suggested laboratory evaluations Based on background antiretroviral therapy
Warnings None
Full Prescribing Information http://www.tivicay.com

 

Links to Antiretroviral Sections
Nucleoside & Nucleotide Reverse Transcriptase Inhibitors (NRTI)
AZT  |  ddI  |  d4T  |  3TC  |  ABC  |  FTC  |  TDF  ||| Coformulation NRTI:  Combivir  |  Trizivir  |  Epzicom  |  Truvada
Nonnucleoside Reverse Transcriptase Inhibitors (NNRTI)
efavirenz  |  nevirapine  |  delavirdine  |  etravirine  |  rilpivirine
Protease Inhibitors (PI)  |  Boosted Protease Inhibitors
saquinavir  indinavir  |  ritonavir  |  nelfinavir  |  lopinavir + ritonavir  |  atazanavir  |  fosamprenavir  | tipranavir
Co-receptor Inhibitors
maraviroc
Fusion Inhibitors
enfuvirtide
Integrase Inhibitors
raltegravir  |  elvitegravir  |  dolutegravir
Antiretroviral Metabolic Inhibitors
cobicistat  |  ritonavir
Coformulations
Atripla (efavirenz/tenofovir/emtricitabine)  |  Complera (rilpivirine/tenofovir/emtricitabine)  | Stribild (elvitegravir/cobicistat/tenofovir/emtricitabine)

 

 

Quick Menu / Table of Contents
Introduction Principles Management NRTI Info NNRTI Info
PI Info Fusion Inhibitors Coreceptor Inhibitors Integrase Inhibitors Drug Summary
Coformulation Antiretroviral Therapy
Investigational Adherence Lab Evaluation Resistance Tests PEP
Antiretroviral Tables OI Prevention Vaccinations TB Therapy Hepatitis Therapy
OI Diagnosis OI Therapy Bibliography Links Palliative Therapy

 


Updated 11/10/2013